Study identifier:D9673R00025
ClinicalTrials.gov identifier:NCT05592483
EudraCT identifier:N/A
CTIS identifier:N/A
A multi-center, multi-country prospective observational study of patients initiating T-DXd in the first or second treatment line for HER2+, and HER2-low unresectable and/or metastatic breast cancer
Breast Cancer
Phase 4
No
-
All
28
Observational
18 Years - 130 Years
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Jun 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
HER2+ Cohort Patients with HER2+ unresectable and/or mBC who are prescribed T-DXd and have received a prior anti-HER2 based regimen. | Other: None (Observational Study) Not Applicable since observational study Other Name: Observational study |
HER2-low cohort Patients with HER2-low unresectable and/or mBC who are prescribed T-DXd and have received a prior chemotherapy. | Other: None (Observational Study) Not Applicable since observational study Other Name: Observational study |